NCT05243641: Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER2 and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

NCT05243641
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MET, HER2
Breast Cancer Tissue: Inflammatory breast cancer (IBC)
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only patients with HER2-negative breast cancer are eligible for phase 2
Exclusions: Patients with unstable and symptomatic brain metastasis – see trial for details
https://ClinicalTrials.gov/show/NCT05243641

NCT05120960: A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

NCT05120960
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MET
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Breast cancer patients are eligible for the dose exploration (phase 1a, group A of the study); Participants must have at least 1 measurable brain metastasis present; Participants must require surgical resection; For patients with prior whole brain radiation therapy or SRS, progression in any measurable brain metastasis must have occurred at least 1 month after the end of radiation therapy
Exclusions: 
https://ClinicalTrials.gov/show/NCT05120960

Up ↑